National Research Corporation (NRC) is a provider of analytics and insights that facilitate revenue growth, patient, employee and customer retention and patient engagement for healthcare providers, payers and other healthcare organizations. The Company's portfolio of subscription-based solutions provides information and analysis to healthcare organizations and payers across a range of mission-critical, constituent-related elements, including patient experience and satisfaction, community population health risks, workforce engagement, community perceptions, and physician engagement. The Company's clients range from acute care hospitals and post-acute providers, such as home health, long term care and hospice, to numerous payer organizations. The Company derives its revenue from its annually renewable services, which include performance measurement and improvement services, healthcare analytics and governance education services.
Industry, Sector and Symbol
Industry Commercial physical research
Sub-IndustryN/A
SectorBusiness Services
Phone402-475-2525
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$119.69 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date11/5/2019 (Estimated)
OptionableNot Optionable
National Research (NASDAQ:NRC) Frequently Asked Questions
What is National Research's stock symbol?
National Research trades on the NASDAQ under the ticker symbol "NRC."
How often does National Research pay dividends? What is the dividend yield for National Research?
National Research announced a quarterly dividend on Wednesday, June 5th. Shareholders of record on Friday, June 28th will be given a dividend of $0.19 per share on Monday, July 15th. This represents a $0.76 dividend on an annualized basis and a yield of 1.17%. The ex-dividend date of this dividend is Thursday, June 27th. View National Research's Dividend History.
How were National Research's earnings last quarter?
National Research Co. (NASDAQ:NRC) posted its quarterly earnings results on Tuesday, May, 7th. The company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.31 by $0.01. The business earned $31.48 million during the quarter, compared to analysts' expectations of $33.50 million. National Research had a net margin of 24.59% and a return on equity of 124.11%. View National Research's Earnings History.
When is National Research's next earnings date?
What is the consensus analysts' recommendation for National Research?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for National Research in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for National Research.
Has National Research been receiving favorable news coverage?
Headlines about NRC stock have been trending negative this week, InfoTrie reports. The research firm scores the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. National Research earned a coverage optimism score of -2.3 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for National Research.
Who are some of National Research's key competitors?
Some companies that are related to National Research include Charles River Laboratories Intl. (CRL), PRA Health Sciences (PRAH), Syneos Health (SYNH), BTG (BTGGF), Medpace (MEDP), Intrexon (XON), STARPHARMA HOLD/S (SPHRY), Sorrento Therapeutics (SRNE), Pieris Pharmaceuticals (PIRS), Eloxx Pharmaceuticals (ELOX), Luna Innovations (LUNA), Anavex Life Sciences (AVXL), BIOQUAL (BIOQ), HedgePath Pharmaceuticals (HPPI) and Bioanalytical Systems (BASI).
What other stocks do shareholders of National Research own?
Who are National Research's key executives?
National Research's management team includes the folowing people:
- Steven D. Jackson, President (Age 41)
- Michael D. Hays, Chief Executive Officer, Director (Age 62)
- Kevin R. Karas, Chief Financial Officer, Senior Vice President - Finance, Treasurer, Secretary (Age 59)
- John N. Nunnelly, Lead Independent Director (Age 64)
- Donald M. Berwick M.D., Independent Director (Age 70)
- JoAnn M. Martin, Independent Director (Age 62)
- Barbara J Mowry, Independent Director (Age 69)
Who are National Research's major shareholders?
National Research's stock is owned by a number of of retail and institutional investors. Top institutional investors include Kayne Anderson Rudnick Investment Management LLC (12.60%), BlackRock Inc. (2.86%), Conestoga Capital Advisors LLC (2.52%), Vanguard Group Inc. (2.26%), Renaissance Technologies LLC (2.07%) and Northern Trust Corp (0.71%). Company insiders that own National Research stock include Amandla Mk Trust, K/I/E Trust Under Agreement 10, K/I/E/Trust Under Agreement 3/ and Kevin R Karas. View Institutional Ownership Trends for National Research.
Which institutional investors are selling National Research stock?
NRC stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Kayne Anderson Rudnick Investment Management LLC, Spitfire Capital LLC, WINTON GROUP Ltd, Zebra Capital Management LLC, Strs Ohio, First Quadrant L P CA and Cowen Prime Services LLC. Company insiders that have sold National Research company stock in the last year include Amandla Mk Trust, K/I/E Trust Under Agreement 10, K/I/E/Trust Under Agreement 3/ and Kevin R Karas. View Insider Buying and Selling for National Research.
Which institutional investors are buying National Research stock?
NRC stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Nuveen Asset Management LLC, BlackRock Inc., Renaissance Technologies LLC, Isthmus Partners LLC, Conestoga Capital Advisors LLC, Bessemer Group Inc. and Panagora Asset Management Inc.. View Insider Buying and Selling for National Research.
How do I buy shares of National Research?
Shares of NRC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is National Research's stock price today?
One share of NRC stock can currently be purchased for approximately $64.89.
How big of a company is National Research?
National Research has a market capitalization of $1.61 billion and generates $119.69 million in revenue each year. The company earns $30.05 million in net income (profit) each year or $1.04 on an earnings per share basis. View Additional Information About National Research.
What is National Research's official website?
How can I contact National Research?
National Research's mailing address is 1245 Q STREET, LINCOLN NE, 68508. The company can be reached via phone at 402-475-2525.
MarketBeat Community Rating for National Research (NASDAQ NRC)
MarketBeat's community ratings are surveys of what our community members think about National Research and other stocks. Vote "Outperform" if you believe NRC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NRC will underperform the S&P 500 over the long term. You may vote once every thirty days.
